Iñigo Rua-Figueroa, Irene Altabás-González, Coral Mouriño, Karen Roberts, Andrea Hernández-Martín, Ivette Casafont-Solé, Judit Font-Urgelles, Jose A Román-Ivorra, Marta de la Rubia Navarro, Maria Galindo-Izquierdo, Tarek C Salman-Monte, Javier Narváez, Paola Vidal-Montal, Maria Jesús García-Villanueva, Sandra Garrote-Corral, Maria Angeles Blazquez-Canamero, Carlos Marras Fernandez-Cid, Maria Piqueras-García, Julia Martínez-Barrio, Marina Sánchez-Lucas, Josefina Cortés-Hernández, Eleonora Penzo, Jaime Calvo-Alén, Juan Ramón de Dios, Belén Alvarez-Rodríguez, Margarida Vasques-Rocha, Eva Tomero, Raul Menor-Almagro, Myriam Gandía, José A Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos-Giráldez, Carmen Trapero-Pérez, Elvira Diez, Clara Moriano, Alejandro Muñoz-Jiménez, José María Pego-Reigosa
{"title":"系统性红斑狼疮患者能否减少贝利木单抗的剂量？","authors":"Iñigo Rua-Figueroa, Irene Altabás-González, Coral Mouriño, Karen Roberts, Andrea Hernández-Martín, Ivette Casafont-Solé, Judit Font-Urgelles, Jose A Román-Ivorra, Marta de la Rubia Navarro, Maria Galindo-Izquierdo, Tarek C Salman-Monte, Javier Narváez, Paola Vidal-Montal, Maria Jesús García-Villanueva, Sandra Garrote-Corral, Maria Angeles Blazquez-Canamero, Carlos Marras Fernandez-Cid, Maria Piqueras-García, Julia Martínez-Barrio, Marina Sánchez-Lucas, Josefina Cortés-Hernández, Eleonora Penzo, Jaime Calvo-Alén, Juan Ramón de Dios, Belén Alvarez-Rodríguez, Margarida Vasques-Rocha, Eva Tomero, Raul Menor-Almagro, Myriam Gandía, José A Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos-Giráldez, Carmen Trapero-Pérez, Elvira Diez, Clara Moriano, Alejandro Muñoz-Jiménez, José María Pego-Reigosa","doi":"10.1093/rheumatology/keae270","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyse treatment modalities, and determine impact on control of disease activity.</p><p><strong>Methods: </strong>Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared.</p><p><strong>Results: </strong>A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in nine patients receiving subcutaneous BEL and in six patients receiving intravenous BEL. The dose per administration was reduced in 16 patients. Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively [not statistically significant (NS)]. As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline).</p><p><strong>Conclusion: </strong>Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable.</p>","PeriodicalId":21255,"journal":{"name":"Rheumatology","volume":" ","pages":"1220-1224"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?\",\"authors\":\"Iñigo Rua-Figueroa, Irene Altabás-González, Coral Mouriño, Karen Roberts, Andrea Hernández-Martín, Ivette Casafont-Solé, Judit Font-Urgelles, Jose A Román-Ivorra, Marta de la Rubia Navarro, Maria Galindo-Izquierdo, Tarek C Salman-Monte, Javier Narváez, Paola Vidal-Montal, Maria Jesús García-Villanueva, Sandra Garrote-Corral, Maria Angeles Blazquez-Canamero, Carlos Marras Fernandez-Cid, Maria Piqueras-García, Julia Martínez-Barrio, Marina Sánchez-Lucas, Josefina Cortés-Hernández, Eleonora Penzo, Jaime Calvo-Alén, Juan Ramón de Dios, Belén Alvarez-Rodríguez, Margarida Vasques-Rocha, Eva Tomero, Raul Menor-Almagro, Myriam Gandía, José A Gómez-Puerta, Beatriz Frade-Sosa, Consuelo Ramos-Giráldez, Carmen Trapero-Pérez, Elvira Diez, Clara Moriano, Alejandro Muñoz-Jiménez, José María Pego-Reigosa\",\"doi\":\"10.1093/rheumatology/keae270\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyse treatment modalities, and determine impact on control of disease activity.</p><p><strong>Methods: </strong>Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared.</p><p><strong>Results: </strong>A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in nine patients receiving subcutaneous BEL and in six patients receiving intravenous BEL. The dose per administration was reduced in 16 patients. Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively [not statistically significant (NS)]. As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline).</p><p><strong>Conclusion: </strong>Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable.</p>\",\"PeriodicalId\":21255,\"journal\":{\"name\":\"Rheumatology\",\"volume\":\" \",\"pages\":\"1220-1224\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/keae270\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/rheumatology/keae270","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?
Objectives: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyse treatment modalities, and determine impact on control of disease activity.
Methods: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared.
Results: A total of 324 patients were included. The dose was reduced in 29 patients (8.9%). The dosing interval was increased in nine patients receiving subcutaneous BEL and in six patients receiving intravenous BEL. The dose per administration was reduced in 16 patients. Pre-reduction status was remission (2021 DORIS) in 15/26 patients (57.7%) and LLDAS in 23/26 patients (88.5%). After reduction, 2/24 patients (8.3%) and 3/22 patients (13.6%) lost remission at 6 months and 12 months, respectively [not statistically significant (NS)]. As for LLDAS, 2/23 patients (8.7%) and 2/21 patients (9.5%) lost their status at 6 and 12 months, respectively (NS). Significantly fewer patients were taking glucocorticoids (GCs) at their 12-month visit, although the median dose of GCs was higher at the 12-month visit (5 [0.62-8.75] vs 2.5 [0-5] at baseline).
Conclusion: Doses of BEL can be reduced with no relevant changes in disease activity-at least in the short term-in a significant percentage of patients, and most maintain the reduced dose. However, increased clinical or serologic activity may be observed in some patients. Consequently, tighter post-reduction follow-up is advisable.
期刊介绍：
Rheumatology strives to support research and discovery by publishing the highest quality original scientific papers with a focus on basic, clinical and translational research. The journal’s subject areas cover a wide range of paediatric and adult rheumatological conditions from an international perspective. It is an official journal of the British Society for Rheumatology, published by Oxford University Press.
Rheumatology publishes original articles, reviews, editorials, guidelines, concise reports, meta-analyses, original case reports, clinical vignettes, letters and matters arising from published material. The journal takes pride in serving the global rheumatology community, with a focus on high societal impact in the form of podcasts, videos and extended social media presence, and utilizing metrics such as Altmetric. Keep up to date by following the journal on Twitter @RheumJnl.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
